Rationale and design of REAC-TAVI 2: single antiplatelet treatment with ticagrelor versus aspirin after transcatheter aortic valve implantation.
Hemelrijk K, Jimenez-Diaz VA, Vilchez JP, Oteo JF, Gomez-Blazquez I, Sabate M, Vilalta V, Jofresa AB, Asmarats L, Amat-Santos IJ, Tello-Montoliu A, de la Torre JM, Flores X, Gheorghe L, Peral V, Muñoz-Garcia AJ, Alfonso F, Tirado-Conte G, Brugaletta S, Veiga G, Rodriguez-Gabella T, Regueiro A, De Lara JG, Valle-Fernandez RD, Nodar JMR, Mazuecos JJ, Pan M, Baz JA, Fernández JFD, Guerreiro C, Jorge E, Silva MT, Marques JS, Rodrigues I, Neves D, Braga JP, Testa L, Costa G, Stefanini G, Pesarini G, Sisinni A, Capodanno D, Ribichini F, Salvadores PJ, Delewi R, Angiolillo DJ, Garcia-Garcia HM, Iñiguez A, Nombela-Franco L; REAC-TAVI 2 Investigators.
Hemelrijk K, et al. Among authors: marques js.
Am Heart J. 2025 Oct 31:107293. doi: 10.1016/j.ahj.2025.107293. Online ahead of print.
Am Heart J. 2025.
PMID: 41177202